Benutzer: Gast  Login
Autor(en):
Eckel, F.; Delius, S. von; Mayr, M.; Dobritz, M.; Fend, F.; Hosius, C.; Schleyer, E.; Schulte-Frohlinde, E.; Schmid, R. M.; Lersch, C. 
Titel:
Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma 
Abstract:
Objectives: No effective chemotherapy for advanced hepatocellular carcinoma (HCC) exists. Expression of the platelet-derived growth factor receptor (PDGFR) has been demonstrated in HCC, which may derive from hepatic stem cells that express c-kit. The aim of this trial was to evaluate imatinib, a tyrosine kinase inhibitor of PDGFR and c-kit, in patients with advanced HCC and impaired liver function. Patients and Methods: Patients were treated with 400–600 mg imatinib daily. Immunohistochemical st...    »
 
Stichworte:
c-kit; Hepatocellular carcinoma; Imatinib; Phase II clinical trials; Platelet-derived growth factor receptor 
Zeitschriftentitel:
Oncology 
Jahr:
2005 
Band / Volume:
69 
Heft / Issue:
Seitenangaben Beitrag:
363--371 
Verlag / Institution:
S. Karger AG 
Verlagsort:
Basel, Switzerland 
Print-ISSN:
1423-0232 
E-ISSN:
1423-0232 
Hinweise:
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.